FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a bispecific single-domain antibody for inhibiting protein-induced IL-5 or induced IL-4Rα cell proliferation, a method for production thereof, as well as a drug containing same. Also disclosed is an isolated nucleic acid molecule coding said antibody, as well as a vector and a cell containing same.
EFFECT: invention is effective for treating induced IL-4Rα diseases.
11 cl, 9 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED SINGLE-DOMAIN ANTIBODY TO IL-4Rα AND ITS USE | 2021 |
|
RU2816867C1 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| IL4R-BINDING ANTIBODIES AND USE THEREOF | 2021 |
|
RU2834713C1 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2838943C1 |
| KIR3DL3 INHIBITORY RECEPTOR OF IMMUNE SYSTEM AND USE THEREOF | 2020 |
|
RU2827900C1 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
